Shanghai Junshi Biosciences Co (FRA:8SJ) Margin of Safety % (DCF Dividends Based): N/A (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8SJ Shanghai Junshi Biosciences Co Ltd FRA:8SJ
59 GF Score
Price €1.95
GF Value €3.43
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Shanghai Junshi Biosciences Co Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Shanghai Junshi Biosciences Co's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

FRA:8SJ vs VRTX, REGN, ALNY: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, Shanghai Junshi Biosciences Co's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shanghai Junshi Biosciences Co Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Junshi Biosciences Co's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Shanghai Junshi Biosciences Co's Margin of Safety % (DCF Dividends Based) falls into.


FRA:8SJ
59GF Score
Shanghai Junshi Biosciences Co Ltd FRA:8SJ
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Shanghai Junshi Biosciences Co (FRA:8SJ) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Junshi Biosciences Co stock appears to be undervalued. The current stock price of €1.95 is trading 43.1% below its estimated GF Value™ of €3.43. GuruFocus considers Shanghai Junshi Biosciences Co to be Significantly Undervalued.

Key valuation signals for FRA:8SJ:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: €3.43 vs. price of €1.95 (43.1% below fair value)
  • GF Score™: 59/100 with 5 warning signs

No single metric tells the full story. See the FRA:8SJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Junshi Biosciences Co Business Description

Address No. 987 Cai Lun Road, Level 4, China (Shanghai) Pilot Free Trade Zone, Shanghai, CHN
Shanghai Junshi Biosciences Co Ltd is mainly involved in the discovery, development, and commercialisation of therapeutic drugs. It focuses on the development and commercialization of several kinds of drugs, ranging from monoclonal antibodies to various drug modalities, including small molecules, ADCs, bi-specific or multi-specific antibodies, fusion proteins, nucleic acid drugs, and vaccines, as well as the exploration of next-generation therapies, including those for cancer and autoimmune diseases. The Group's portfolio includes commercialized drugs such as Tuoyi, Junmaikang, Mindewei, and Junshida, as well as products in clinical studies or in the marketing application stage. Geographically, it derives maximum revenue from Mainland China, and the rest from USA, India, and other markets.
59GF Score

Get the complete analysis for FRA:8SJ

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.95
Price
€3.43
GF Value